Live search
TopFind is fetching the latest matches for your search.
We reviewed 8 live results for amgevita and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilar and Adalimumab.
Sumber: Amgen Biotechnology Singapore Pte Ltd
Deskripsi
Amgevita is a biosimilar to Humira (adalimumab) registered in Singapore for the treatment of various inflammatory conditions, including rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. As an anti-inflammatory biologic, it provides a high-quality, cost-effective alternative for patients managing chronic autoimmune diseases.
Paling cocok untuk
rheumatoid arthritis patients, plaque psoriasis treatment and cost-effective biologic access
Penilaian
Sumber: Amgen Inc.
Deskripsi
Amgevita is the international brand name for Amgen's adalimumab biosimilar, widely used in Canada, Europe, and New Zealand. It is indicated for the treatment of autoimmune diseases such as Hidradenitis Suppurativa, Uveitis, and juvenile idiopathic arthritis, alongside major inflammatory conditions. The product is available in convenient formats including single-use pre-filled pens and syringes.
Paling cocok untuk
international patients, uveitis treatment, hidradenitis suppurativa care and ankylosing spondylitis patients
Penilaian
Sumber: Amgen (Thailand) Limited
Deskripsi
Amgevita is a biosimilar to Humira, containing the active substance adalimumab. It is used as a biologic therapy for inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and plaque psoriasis. Available in Thailand as a solution for injection in 20 mg/0.4 ml and 40 mg/0.8 ml pre-filled syringes or autoinjectors, it is classified as a Special Controlled Drug that requires professional medical supervision for prescription and dispensing.
Paling cocok untuk
rheumatoid arthritis patients, biosimilar drug preference, chronic inflammation management and specialized biologic therapy
Penilaian
| Bandingkan | Amgevita | Amgevita (adalimumab) | Amgevita (adalimumab-atto) |
|---|---|---|---|
| Sumber | Amgen Biotechnology Singapore Pte Ltd | Amgen Inc. | Amgen (Thailand) Limited |
| Deskripsi | Amgevita is a biosimilar to Humira (adalimumab) registered in Singapore for the treatment of various inflammatory conditions, including rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. As an anti-inflammatory biologic, it provides a high-quality, cost-effective alternative for patients managing chronic autoimmune diseases. | Amgevita is the international brand name for Amgen's adalimumab biosimilar, widely used in Canada, Europe, and New Zealand. It is indicated for the treatment of autoimmune diseases such as Hidradenitis Suppurativa, Uveitis, and juvenile idiopathic arthritis, alongside major inflammatory conditions. The product is available in convenient formats including single-use pre-filled pens and syringes. | Amgevita is a biosimilar to Humira, containing the active substance adalimumab. It is used as a biologic therapy for inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and plaque psoriasis. Available in Thailand as a solution for injection in 20 mg/0.4 ml and 40 mg/0.8 ml pre-filled syringes or autoinjectors, it is classified as a Special Controlled Drug that requires professional medical supervision for prescription and dispensing. |
| Paling cocok untuk | rheumatoid arthritis patients, plaque psoriasis treatment and cost-effective biologic access | international patients, uveitis treatment, hidradenitis suppurativa care and ankylosing spondylitis patients | rheumatoid arthritis patients, biosimilar drug preference, chronic inflammation management and specialized biologic therapy |
| Tag | |||
| Aksi | Lihat detail | Lihat detail | Lihat detail |
| Penilaian |
Jika Anda ingin memulai dari opsi yang paling seimbang, saya merekomendasikan:
"Amgevita from Amgen Biotechnology Singapore Pte Ltd."
Saya memilih ini karena Amgevita is a registered, cost-effective adalimumab biosimilar in Singapore that is often supported by government medication subsidies.